Drug Resistance Updates
Volume 13, Issue 4 , Pages 119-131 , August 2010

Translating DNA damage into cancer cell death—A roadmap for E2F1 apoptotic signalling and opportunities for new drug combinations to overcome chemoresistance

Received 26 May 2010 ,Revised 21 June 2010 ,Accepted 22 June 2010.

References 

  1. Abraham H, Somogyvari-Vigh A, Maderdrut JL, Vigh S, Arimura A. Filament size influences temperature changes and brain damage following middle cerebral artery occlusion in rats. Exp. Brain Res. 2002;142:131–138
  2. Agger K, Santoni-Rugiu E, Holmberg C, Karlstrom O, Helin K. Conditional E2F1 activation in transgenic mice causes testicular atrophy and dysplasia mimicking human CIS. Oncogene. 2005;24:780–789
  3. Alla V, Engelmann D, Niemetz A, Pahnke J, Schmidt A, Kunz M, et al. E2F1 in melanoma progression and metastasis. J. Natl. Cancer Inst. 2010;102:127–133
  4. Ambrosini G, Sambol EB, Carvajal D, Vassilev LT, Singer S, Schwartz GK. Mouse double minute antagonist Nutlin-3a enhances chemotherapy-induced apoptosis in cancer cells with mutant p53 by activating E2F1. Oncogene. 2007;26:3473–3481
  5. Banerjee D, Gorlick R, Liefshitz A, Danenberg K, Danenberg PC, Danenberg PV, et al. Levels of E2F-1 expression are higher in lung metastasis of colon cancer as compared with hepatic metastasis and correlate with levels of thymidylate synthase. Cancer Res. 2000;60:2365–2367
  6. Banerjee D, Schnieders B, Fu JZ, Adhikari D, Zhao SC, Bertino JR. Role of E2F-1 in chemosensitivity. Cancer Res. 1998;58:4292–4296
  7. Banin S, Moyal L, Shieh S, Taya Y, Anderson CW, Chessa L, et al. Enhanced phosphorylation of p53 by ATM in response to DNA damage. Science. 1998;281:1674–1677
  8. Bates S, Phillips AC, Clark PA, Stott F, Peters G, Ludwig RL, et al. p14ARF links the tumour suppressors RB and p53. Nature. 1998;395:124–125
  9. Belvedere O, Puglisi F, Di Loreto C, Cataldi P, Guglielmi A, Aschele C, et al. Lack of correlation between immunohistochemical expression of E2F-1, thymidylate synthase expression and clinical response to 5-fluorouracil in advanced colorectal cancer. Ann. Oncol. 2004;15:55–58
  10. Ben Shachar B, Feldstein O, Hacohen D, Ginsberg D. The Tumor suppressor maspin mediates E2F1-induced sensitivity of cancer cells to chemotherapy. Mol. Cancer Res. 2010;8:363–372
  11. Berkovich E, Ginsberg D. ATM is a target for positive regulation by E2F-1. Oncogene. 2003;22:161–167
  12. Blattner C, Sparks A, Lane D. Transcription factor E2F-1 is upregulated in response to DNA damage in a manner analogous to that of p53. Mol. Cell. Biol. 1999;19:3704–3713
  13. Britschgi A, Trinh E, Rizzi M, Jenal M, Ress A, Tobler A, et al. DAPK2 is a novel E2F1/KLF6 target gene involved in their proapoptotic function. Oncogene. 2008;27:5706–5716
  14. Canman CE, Lim DS. The role of ATM in DNA damage responses and cancer. Oncogene. 1998;17:3301–3308
  15. Cao Q, Xia Y, Azadniv M, Crispe IN. The E2F-1 transcription factor promotes caspase-8 and bid expression, and enhances Fas signaling in T cells. J. Immunol. 2004;173:1111–1117
  16. Carcagno AL, Ogara MF, Sonzogni SV, Marazita MC, Sirkin PF, Ceruti JM, et al. E2F1 transcription is induced by genotoxic stress through ATM/ATR activation. IUBMB Life. 2009;61:537–543
  17. Cassimere EK, Pyndiah S, Sakamuro D. The c-MYC-interacting proapoptotic tumor suppressor BIN1 is a transcriptional target for E2F1 in response to DNA damage. Cell Death Differ. 2009;16:1641–1653
  18. Chaussepied M, Ginsberg D. Transcriptional regulation of AKT activation by E2F. Mol. Cell. 2004;16:831–837
  19. Chen D, Pacal M, Wenzel P, Knoepfler PS, Leone G, Bremner R. Division and apoptosis of E2f-deficient retinal progenitors. Nature. 2009;462:925–929
  20. Chen G, Goeddel DV. TNF-R1 signaling: a beautiful pathway. Science. 2002;296:1634–1635
  21. Chen PL, Riley DJ, Chen Y, Lee WH. Retinoblastoma protein positively regulates terminal adipocyte differentiation through direct interaction with C/EBPs. Genes Dev. 1996;10:2794–2804
  22. Chen WY, Wang DH, Yen RC, Luo J, Gu W, Baylin SB. Tumor suppressor HIC1 directly regulates SIRT1 to modulate p53-dependent DNA-damage responses. Cell. 2005;123:437–448
  23. Chong JL, Wenzel PL, Saenz-Robles MT, Nair V, Ferrey A, Hagan JP, et al. E2f1-3 switch from activators in progenitor cells to repressors in differentiating cells. Nature. 2009;462:930–934
  24. Cole MD, Cowling VH. Specific regulation of mRNA cap methylation by the c-Myc and E2F1 transcription factors. Oncogene. 2009;28:1169–1175
  25. Crawford NP, Qian X, Ziogas A, Papageorge AG, Boersma BJ, Walker RC, et al. Rrp1b, a new candidate susceptibility gene for breast cancer progression and metastasis. PLoS Genet. 2007;3:e214
  26. Croxton R, Ma Y, Song L, Haura EB, Cress WD. Direct repression of the Mcl-1 promoter by E2F1. Oncogene. 2002;21:1359–1369
  27. Dai JM, Wang ZY, Sun DC, Lin RX, Wang SQ. SIRT1 interacts with p73 and suppresses p73-dependent transcriptional activity. J. Cell. Physiol. 2007;210:161–166
  28. DeGregori J. The genetics of the E2F family of transcription factors: shared functions and unique roles. Biochim. Biophys. Acta. 2002;1602:131–150
  29. Dick FA, Dyson N. pRB contains an E2F1-specific binding domain that allows E2F1-induced apoptosis to be regulated separately from other E2F activities. Mol. Cell. 2003;12:639–649
  30. Dijkers PF, Medema RH, Lammers JW, Koenderman L, Coffer PJ. Expression of the pro-apoptotic Bcl-2 family member Bim is regulated by the forkhead transcription factor FKHR-L1. Curr. Biol. 2000;10:1201–1204
  31. Dong YB, Yang HL, Elliott MJ, Liu TJ, Stilwell A, Atienza C, et al. Adenovirus-mediated E2F-1 gene transfer efficiently induces apoptosis in melanoma cells. Cancer. 1999;86:2021–2033
  32. Dong YB, Yang HL, Elliott MJ, McMasters KM. Adenovirus-mediated E2F-1 gene transfer sensitizes melanoma cells to apoptosis induced by topoisomerase II inhibitors. Cancer Res. 2002;62:1776–1783
  33. Dyson N. The regulation of E2F by pRB-family proteins. Genes Dev. 1998;12:2245–2262
  34. Eischen CM, Packham G, Nip J, Fee BE, Hiebert SW, Zambetti GP, et al. Bcl-2 is an apoptotic target suppressed by both c-Myc and E2F-1. Oncogene. 2001;20:6983–6993
  35. Elliott MJ, Baker JD, Dong YB, Yang HL, Gleason JF, McMasters KM. Inhibition of cyclin A kinase activity in E2F-1 chemogene therapy of colon cancer. Tumour Biol. 2002;23:324–336
  36. Elliott MJ, Farmer MR, Atienza C, Stilwell A, Dong YB, Yang HL, et al. E2F-1 gene therapy induces apoptosis and increases chemosensitivity in human pancreatic carcinoma cells. Tumour Biol. 2002;23:76–86
  37. Emmrich S, Pützer BM. Checks and balances: E2F-microRNA crosstalk in cancer control. Cell Cycle. 2010;9:2555–2567
  38. Engelmann D, Knoll S, Ewerth D, Steder M, Stoll A, Putzer BM. Functional interplay between E2F1 and chemotherapeutic drugs defines immediate E2F1 target genes crucial for cancer cell death. Cell. Mol. Life Sci. 2010;67:931–948
  39. Eymin B, Gazzeri S, Brambilla C, Brambilla E. Distinct pattern of E2F1 expression in human lung tumours: E2F1 is upregulated in small cell lung carcinoma. Oncogene. 2001;20:1678–1687
  40. Field SJ, Tsai FY, Kuo F, Zubiaga AM, Kaelin WG, Livingston DM, et al. E2F-1 functions in mice to promote apoptosis and suppress proliferation. Cell. 1996;85:549–561
  41. Fortin A, MacLaurin JG, Arbour N, Cregan SP, Kushwaha N, Callaghan SM, et al. The proapoptotic gene SIVA is a direct transcriptional target for the tumor suppressors p53 and E2F1. J. Biol. Chem. 2004;279:28706–28714
  42. Freeman SN, Ma Y, Cress WD. RhoBTB2 (DBC2) is a mitotic E2F1 target gene with a novel role in apoptosis. J. Biol. Chem. 2008;283:2353–2362
  43. Fueyo J, Gomez-Manzano C, Yung WK, Liu TJ, Alemany R, McDonnell TJ, et al. Overexpression of E2F-1 in glioma triggers apoptosis and suppresses tumor growth in vitro and in vivo. Nat. Med. 1998;4:685–690
  44. Furukawa Y, Nishimura N, Furukawa Y, Satoh M, Endo H, Iwase S, et al. Apaf-1 is a mediator of E2F-1-induced apoptosis. J. Biol. Chem. 2002;277:39760–39768
  45. Galbiati L, Mendoza-Maldonado R, Gutierrez MI, Giacca M. Regulation of E2F-1 after DNA damage by p300-mediated acetylation and ubiquitination. Cell Cycle. 2005;4:930–939
  46. Gomez-Manzano C, Lemoine MG, Hu M, He J, Mitlianga P, Liu TJ, et al. Adenovirally-mediated transfer of E2F-1 potentiates chemosensitivity of human glioma cells to temozolomide and BCNU. Int. J. Oncol. 2001;19:359–365
  47. Gomez-Manzano C, Mitlianga P, Fueyo J, Lee HY, Hu M, Spurgers KB, et al. Transfer of E2F-1 to human glioma cells results in transcriptional up-regulation of Bcl-2. Cancer Res. 2001;61:6693–6697
  48. Gorgoulis VG, Zacharatos P, Mariatos G, Kotsinas A, Bouda M, Kletsas D, et al. Transcription factor E2F-1 acts as a growth-promoting factor and is associated with adverse prognosis in non-small cell lung carcinomas. J. Pathol. 2002;198:142–156
  49. Gudi R, Barkinge J, Hawkins S, Prabhakar B, Kanteti P. Siva-1 promotes K-48 polyubiquitination of TRAF2 and inhibits TCR-mediated activation of NF-kappaB. J. Environ. Pathol. Toxicol. Oncol. 2009;28:25–38
  50. Hallstrom TC, Mori S, Nevins JR. An E2F1-dependent gene expression program that determines the balance between proliferation and cell death. Cancer Cell. 2008;13:11–22
  51. Hallstrom TC, Nevins JR. Specificity in the activation and control of transcription factor E2F-dependent apoptosis. Proc. Natl. Acad. Sci. U.S.A. 2003;100:10848–10853
  52. Han S, Park K, Bae BN, Kim KH, Kim HJ, Kim YD, et al. E2F1 expression is related with the poor survival of lymph node-positive breast cancer patients treated with fluorouracil, doxorubicin and cyclophosphamide. Breast Cancer Res. Treat. 2003;82:11–16
  53. Hatai T, Matsuzawa A, Inoshita S, Mochida Y, Kuroda T, Sakamaki K, et al. Execution of apoptosis signal-regulating kinase 1 (ASK1)-induced apoptosis by the mitochondria-dependent caspase activation. J. Biol. Chem. 2000;275:26576–26581
  54. Helgason GV, O’Prey J, Ryan KM. Oncogene-induced sensitization to chemotherapy-induced death requires induction as well as deregulation of E2F1. Cancer Res. 2010;70:4074–4080
  55. Hershko T, Chaussepied M, Oren M, Ginsberg D. Novel link between E2F and p53: proapoptotic cofactors of p53 are transcriptionally upregulated by E2F. Cell Death Differ. 2005;12:377–383
  56. Hershko T, Ginsberg D. Up-regulation of Bcl-2 homology 3 (BH3)-only proteins by E2F1 mediates apoptosis. J. Biol. Chem. 2004;279:8627–8634
  57. Hershko T, Korotayev K, Polager S, Ginsberg D. E2F1 modulates p38 MAPK phosphorylation via transcriptional regulation of ASK1 and Wip1. J. Biol. Chem. 2006;281:31309–31316
  58. Hiebert SW, Packham G, Strom DK, Haffner R, Oren M, Zambetti G, et al. E2F-1: DP-1 induces p53 and overrides survival factors to trigger apoptosis. Mol. Cell. Biol. 1995;15:6864–6874
  59. Hofferer M, Wirbelauer C, Humar B, Krek W. Increased levels of E2F-1-dependent DNA binding activity after UV- or gamma-irradiation. Nucleic Acids Res. 1999;27:491–495
  60. Holmberg C, Helin K, Sehested M, Karlstrom O. E2F-1-induced p53-independent apoptosis in transgenic mice. Oncogene. 1998;17:143–155
  61. Hsieh JK, Fredersdorf S, Kouzarides T, Martin K, Lu X. E2F1-induced apoptosis requires DNA binding but not transactivation and is inhibited by the retinoblastoma protein through direct interaction. Genes Dev. 1997;11:1840–1852
  62. Hsieh JK, Yap D, O’Connor DJ, Fogal V, Fallis L, Chan F, et al. Novel function of the cyclin A binding site of E2F in regulating p53-induced apoptosis in response to DNA damage. Mol. Cell. Biol. 2002;22:78–93
  63. Huang Y, Ishiko T, Nakada S, Utsugisawa T, Kato T, Yuan ZM. Role for E2F in DNA damage-induced entry of cells into S phase. Cancer Res. 1997;57:3640–3643
  64. Hunt KK, Deng J, Liu TJ, Wilson-Heiner M, Swisher SG, Clayman G, et al. Adenovirus-mediated overexpression of the transcription factor E2F-1 induces apoptosis in human breast and ovarian carcinoma cell lines and does not require p53. Cancer Res. 1997;57:4722–4726
  65. Ianari A, Gallo R, Palma M, Alesse E, Gulino A. Specific role for p300/CREB-binding protein-associated factor activity in E2F1 stabilization in response to DNA damage. J. Biol. Chem. 2004;279:30830–30835
  66. Ianari A, Natale T, Calo E, Ferretti E, Alesse E, Screpanti I, et al. Proapoptotic function of the retinoblastoma tumor suppressor protein. Cancer Cell. 2009;15:184–194
  67. Inoue Y, Kitagawa M, Taya Y. Phosphorylation of pRB at Ser612 by Chk1/2 leads to a complex between pRB and E2F-1 after DNA damage. EMBO J. 2007;26:2083–2093
  68. Irwin M, Marin MC, Phillips AC, Seelan RS, Smith DI, Liu W, et al. Role for the p53 homologue p73 in E2F-1-induced apoptosis. Nature. 2000;407:645–648
  69. Iwamoto M, Banerjee D, Menon LG, Jurkiewicz A, Rao PH, Kemeny NE, et al. Overexpression of E2F-1 in lung and liver metastases of human colon cancer is associated with gene amplification. Cancer Biol. Ther. 2004;3:395–399
  70. Jenal M, Trinh E, Britschgi C, Britschgi A, Roh V, Vorburger SA, et al. The tumor suppressor gene hypermethylated in cancer 1 is transcriptionally regulated by E2F1. Mol. Cancer Res. 2009;7:916–922
  71. Jin W, Di G, Li J, Chen Y, Li W, Wu J, et al. TIEG1 induces apoptosis through mitochondrial apoptotic pathway and promotes apoptosis induced by homoharringtonine and velcade. FEBS Lett. 2007;581:3826–3832
  72. Jones RG, Plas DR, Kubek S, Buzzai M, Mu J, Xu Y, et al. AMP-activated protein kinase induces a p53-dependent metabolic checkpoint. Mol. Cell. 2005;18:283–293
  73. Kherrouche Z, Blais A, Ferreira E, De Launoit Y, Monte D. ASK-1 (apoptosis signal-regulating kinase 1) is a direct E2F target gene. Biochem. J. 2006;396:547–556
  74. Kitagawa M, Aonuma M, Lee SH, Fukutake S, McCormick F. E2F-1 transcriptional activity is a critical determinant of Mdm2 antagonist-induced apoptosis in human tumor cell lines. Oncogene. 2008;27:5303–5314
  75. Kuhn H, Liebers U, Gessner C, Schumacher A, Witt C, Schauer J, et al. Adenovirus-mediated E2F-1 gene transfer in nonsmall-cell lung cancer induces cell growth arrest and apoptosis. Eur. Respir. J. 2002;20:703–709
  76. Kwon MJ, Nam ES, Cho SJ, Park HR, Shin HS, Park JH, et al. E2F1 expression predicts outcome in Korean women who undergo surgery for breast carcinoma. Ann. Surg. Oncol. 2010;17:564–571
  77. Lazzerini Denchi E, Helin K. E2F1 is crucial for E2F-dependent apoptosis. EMBO Rep. 2005;6:661–668
  78. Lee JS, Leem SH, Lee SY, Kim SC, Park ES, Kim SB, et al. Expression signature of E2F1 and its associated genes predict superficial to invasive progression of bladder tumors. J. Clin. Oncol. 2010;28:2660–2667
  79. Lee J, Park CK, Park JO, Lim T, Park YS, Lim HY, et al. Impact of E2F-1 expression on clinical outcome of gastric adenocarcinoma patients with adjuvant chemoradiation therapy. Clin. Cancer Res. 2008;14:82–88
  80. Li H, Ray G, Yoo BH, Erdogan M, Rosen KV. Down-regulation of death-associated protein kinase-2 is required for beta-catenin-induced anoikis resistance of malignant epithelial cells. J. Biol. Chem. 2009;284:2012–2022
  81. Li J, Ran C, Li E, Gordon F, Comstock G, Siddiqui H, et al. Synergistic function of E2F7 and E2F8 is essential for cell survival and embryonic development. Dev. Cell. 2008;14:62–75
  82. Li Z, Kreutzer M, Mikkat S, Mise N, Glocker MO, Putzer BM. Proteomic analysis of the E2F1 response in p53-negative cancer cells: new aspects in the regulation of cell survival and death. Proteomics. 2006;6:5735–5745
  83. Lin SY, Rai R, Li K, Xu ZX, Elledge SJ. BRIT1/MCPH1 is a DNA damage responsive protein that regulates the Brca1-Chk1 pathway, implicating checkpoint dysfunction in microcephaly. Proc. Natl. Acad. Sci. U.S.A. 2005;102:15105–15109
  84. Lin WC, Lin FT, Nevins JR. Selective induction of E2F1 in response to DNA damage, mediated by ATM-dependent phosphorylation. Genes Dev. 2001;15:1833–1844
  85. Liu D, Wei Y, Zhou F, Ge Y, Xu J, Chen H, et al. E1AF promotes mithramycin A-induced Huh-7 cell apoptosis depending on its DNA-binding domain. Arch. Biochem. Biophys. 2008;477:20–26
  86. Liu K, Luo Y, Lin FT, Lin WC. TopBP1 recruits Brg1/Brm to repress E2F1-induced apoptosis, a novel pRb-independent and E2F1-specific control for cell survival. Genes Dev. 2004;18:673–686
  87. Liu K, Paik JC, Wang B, Lin FT, Lin WC. Regulation of TopBP1 oligomerization by Akt/PKB for cell survival. EMBO J. 2006;25:4795–4807
  88. Liu TJ, Wang M, Breau RL, Henderson Y, El-Naggar AK, Steck KD, et al. Apoptosis induction by E2F-1 via adenoviral-mediated gene transfer results in growth suppression of head and neck squamous cell carcinoma cell lines. Cancer Gene Ther. 1999;6:163–171
  89. Lize M, Pilarski S, Dobbelstein M. E2F1-inducible microRNA 449a/b suppresses cell proliferation and promotes apoptosis. Cell Death Differ. 2010;17:452–458
  90. Louie MC, McClellan A, Siewit C, Kawabata L. Estrogen receptor regulates E2F1 expression to mediate tamoxifen resistance. Mol. Cancer Res. 2010;8:343–352
  91. Marabese M, Vikhanskaya F, Rainelli C, Sakai T, Broggini M. DNA damage induces transcriptional activation of p73 by removing C-EBPalpha repression on E2F1. Nucleic Acids Res. 2003;31:6624–6632
  92. Markham D, Munro S, Soloway J, O’Connor DP, La Thangue NB. DNA-damage-responsive acetylation of pRb regulates binding to E2F-1. EMBO Rep. 2006;7:192–198
  93. Martinez LA, Goluszko E, Chen HZ, Leone G, Post S, Lozano G, et al. E2F3 is a mediator of DNA damage-induced apoptosis. Mol. Cell. Biol. 2010;30:524–536
  94. McConkey DJ, Zhu K. Mechanisms of proteasome inhibitor action and resistance in cancer. Drug Resist. Updates. 2008;11:164–179
  95. Meng RD, Phillips P, El-Deiry WS. p53-independent increase in E2F-1 expression enhances the cytotoxic effects of etoposide and of adriamycin. Int. J. Oncol. 1999;14:5–14
  96. Merdzhanova G, Edmond V, De Seranno S, Van den Broeck A, Corcos L, Brambilla C, et al. E2F1 controls alternative splicing pattern of genes involved in apoptosis through upregulation of the splicing factor SC35. Cell Death Differ. 2008;15:1815–1823
  97. Milton AH, Khaire N, Ingram L, O’Donnell AJ, La Thangue NB. 14-3-3 proteins integrate E2F activity with the DNA damage response. EMBO J. 2006;25:1046–1057
  98. Miyake H, Hara I, Arakawa S, Kamidono S. Stress protein GRP78 prevents apoptosis induced by calcium ionophore, ionomycin, but not by glycosylation inhibitor, tunicamycin, in human prostate cancer cells. J. Cell. Biochem. 2000;77:396–408
  99. Moon NS, Di Stefano L, Dyson N. A gradient of epidermal growth factor receptor signaling determines the sensitivity of rbf1 mutant cells to E2F-dependent apoptosis. Mol. Cell. Biol. 2006;26:7601–7615
  100. Moon NS, Dyson N. E2F7 and E2F8 keep the E2F family in balance. Dev. Cell. 2008;14:1–3
  101. Moon NS, Frolov MV, Kwon EJ, Di Stefano L, Dimova DK, Morris EJ, et al. Drosophila E2F1 has context-specific pro- and antiapoptotic properties during development. Dev. Cell. 2005;9:463–475
  102. Morris EJ, Michaud WA, Ji JY, Moon NS, Rocco JW, Dyson NJ. Functional identification of Api5 as a suppressor of E2F-dependent apoptosis in vivo. PLoS Genet. 2006;2:e196
  103. Nahle Z, Polakoff J, Davuluri RV, McCurrach ME, Jacobson MD, Narita M, et al. Direct coupling of the cell cycle and cell death machinery by E2F. Nat. Cell Biol. 2002;4:859–864
  104. Nguyen KH, Hachem P, Khor LY, Salem N, Hunt KK, Calkins PR, et al. Adenoviral-E2F-1 radiosensitizes p53wild-type and p53null human prostate cancer cells. Int. J. Radiat. Oncol. Biol. Phys. 2005;63:238–246
  105. Nip J, Strom DK, Fee BE, Zambetti G, Cleveland JL, Hiebert SW. E2F-1 cooperates with topoisomerase II inhibition and DNA damage to selectively augment p53-independent apoptosis. Mol. Cell. Biol. 1997;17:1049–1056
  106. Nowak K, Killmer K, Gessner C, Lutz W. E2F-1 regulates expression of FOXO1 and FOXO3a. Biochim. Biophys. Acta. 2007;1769:244–252
  107. Obexer P, Geiger K, Ambros PF, Meister B, Ausserlechner MJ. FKHRL1-mediated expression of Noxa and Bim induces apoptosis via the mitochondria in neuroblastoma cells. Cell Death Differ. 2007;14:534–547
  108. Obexer P, Hagenbuchner J, Unterkircher T, Sachsenmaier N, Seifarth C, Bock G, et al. Repression of BIRC5/survivin by FOXO3/FKHRL1 sensitizes human neuroblastoma cells to DNA damage-induced apoptosis. Mol. Biol. Cell. 2009;20:2041–2048
  109. Osborn AJ, Elledge SJ, Zou L. Checking on the fork: the DNA-replication stress-response pathway. Trends Cell Biol. 2002;12:509–516
  110. Paik JC, Wang B, Liu K, Lue JK, Lin WC. Regulation of E2F1-induced apoptosis by the nucleolar protein RRP1B. J. Biol. Chem. 2010;285:6348–6363
  111. Parr MJ, Manome Y, Tanaka T, Wen P, Kufe DW, Kaelin WG, et al. Tumor-selective transgene expression in vivo mediated by an E2F-responsive adenoviral vector. Nat. Med. 1997;3:1145–1149
  112. Pediconi N, Guerrieri F, Vossio S, Bruno T, Belloni L, Schinzari V, et al. hSirT1-dependent regulation of the PCAF-E2F1-p73 apoptotic pathway in response to DNA damage. Mol. Cell. Biol. 2009;29:1989–1998
  113. Pediconi N, Ianari A, Costanzo A, Belloni L, Gallo R, Cimino L, et al. Differential regulation of E2F1 apoptotic target genes in response to DNA damage. Nat. Cell Biol. 2003;5:552–558
  114. Phillips AC, Bates S, Ryan KM, Helin K, Vousden KH. Induction of DNA synthesis and apoptosis are separable functions of E2F-1. Genes Dev. 1997;11:1853–1863
  115. Phillips AC, Ernst MK, Bates S, Rice NR, Vousden KH. E2F-1 potentiates cell death by blocking antiapoptotic signaling pathways. Mol. Cell. 1999;4:771–781
  116. Pierce AM, Schneider-Broussard R, Gimenez-Conti IB, Russell JL, Conti CJ, Johnson DG. E2F1 has both oncogenic and tumor-suppressive properties in a transgenic model. Mol. Cell. Biol. 1999;19:6408–6414
  117. Polager S, Ginsberg D. E2F mediates sustained G2 arrest and down-regulation of Stathmin and AIM-1 expression in response to genotoxic stress. J. Biol. Chem. 2003;278:1443–1449
  118. Polager S, Ginsberg D. p53 and E2f: partners in life and death. Nat. Rev. Cancer. 2009;9:738–748
  119. Powers JT, Hong S, Mayhew CN, Rogers PM, Knudsen ES, Johnson DG. E2F1 uses the ATM signaling pathway to induce p53 and Chk2 phosphorylation and apoptosis. Mol. Cancer Res. 2004;2:203–214
  120. Prendergast GC, Muller AJ, Ramalingam A, Chang MY. BAR the door: cancer suppression by amphiphysin-like genes. Biochim. Biophys. Acta. 2009;1795:25–36
  121. Pruschy M, Wirbelauer C, Glanzmann C, Bodis S, Krek W. E2F-1 has properties of a radiosensitizer and its regulation by cyclin A kinase is required for cell survival of fibrosarcoma cells lacking p53. Cell Growth Differ. 1999;10:141–146
  122. Qiao L, Wong BC. Targeting apoptosis as an approach to gastrointestinal cancer therapy. Drug Resist. Updates. 2009;12:55–64
  123. Qin XQ, Livingston DM, Kaelin WG, Adams PD. Deregulated transcription factor E2F-1 expression leads to S-phase entry and p53-mediated apoptosis. Proc. Natl. Acad. Sci. U.S.A. 1994;91:10918–10922
  124. Racek T, Buhlmann S, Rust F, Knoll S, Alla V, Putzer BM. Transcriptional repression of the prosurvival endoplasmic reticulum chaperone GRP78/BIP by E2F1. J. Biol. Chem. 2008;283:34305–34314
  125. Rai R, Dai H, Multani AS, Li K, Chin K, Gray J, et al. BRIT1 regulates early DNA damage response, chromosomal integrity, and cancer. Cancer Cell. 2006;10:145–157
  126. Real PJ, Sanz C, Gutierrez O, Pipaon C, Zubiaga AM, Fernandez-Luna JL. Transcriptional activation of the proapoptotic bik gene by E2F proteins in cancer cells. FEBS Lett. 2006;580:5905–5909
  127. Real S, Espada L, Espinet C, Santidrian AF, Tauler A. Study of the in vivo phosphorylation of E2F1 on Ser403. Biochim. Biophys. Acta. 2010;1803:912–918
  128. Ribeiro A, Bronk SF, Roberts PJ, Urrutia R, Gores GJ. The transforming growth factor beta(1)-inducible transcription factor TIEG1, mediates apoptosis through oxidative stress. Hepatology. 1999;30:1490–1497
  129. Rödicker F, Stiewe T, Zimmermann S, Putzer BM. Therapeutic efficacy of E2F1 in pancreatic cancer correlates with TP73 induction. Cancer Res. 2001;61:7052–7055
  130. Rodriguez JM, Glozak MA, Ma Y, Cress WD. Bok, Bcl-2-related ovarian killer, is cell cycle-regulated and sensitizes to stress-induced apoptosis. J. Biol. Chem. 2006;281:22729–22735
  131. Rogoff HA, Pickering MT, Debatis ME, Jones S, Kowalik TF. E2F1 induces phosphorylation of p53 that is coincident with p53 accumulation and apoptosis. Mol. Cell. Biol. 2002;22:5308–5318
  132. Salon C, Merdzhanova G, Brambilla C, Brambilla E, Gazzeri S, Eymin B. E2F-1, Skp2 and cyclin E oncoproteins are upregulated and directly correlated in high-grade neuroendocrine lung tumors. Oncogene. 2007;26:6927–6936
  133. Shan B, Lee WH. Deregulated expression of E2F-1 induces S-phase entry and leads to apoptosis. Mol. Cell. Biol. 1994;14:8166–8173
  134. Shiloh Y. ATM and ATR: networking cellular responses to DNA damage. Curr. Opin. Genet. Dev. 2001;11:71–77
  135. Stanelle J, Pützer BM. E2F1-induced apoptosis: turning killers into therapeutics. Trends Mol. Med. 2006;12:177–185
  136. Stanelle J, Stiewe T, Theseling CC, Peter M, Pützer BM. Gene expression changes in response to E2F1 activation. Nucleic Acids Res. 2002;30:1859–1869
  137. Stevens C, Smith L, La Thangue NB. Chk2 activates E2F-1 in response to DNA damage. Nat. Cell Biol. 2003;5:401–409
  138. Stiewe T, Pützer BM. Role of the p53-homologue p73 in E2F1-induced apoptosis. Nat. Genet. 2000;26:464–469
  139. Tanaka H, Matsumura I, Ezoe S, Satoh Y, Sakamaki T, Albanese C, et al. E2F1 and c-Myc potentiate apoptosis through inhibition of NF-kappaB activity that facilitates MnSOD-mediated ROS elimination. Mol. Cell. 2002;9:1017–1029
  140. Timchenko NA, Wilde M, Darlington GJ. C/EBPalpha regulates formation of S-phase-specific E2F-p107 complexes in livers of newborn mice. Mol. Cell. Biol. 1999;19:2936–2945
  141. Trimarchi JM, Lees JA. Sibling rivalry in the E2F family. Nat. Rev. Mol. Cell Biol. 2002;3:11–20
  142. Tsai KY, Hu Y, Macleod KF, Crowley D, Yamasaki L, Jacks T. Mutation of E2f-1 suppresses apoptosis and inappropriate S phase entry and extends survival of Rb-deficient mouse embryos. Mol. Cell. 1998;2:293–304
  143. Tyagi S, Chabes AL, Wysocka J, Herr W. E2F activation of S phase promoters via association with HCF-1 and the MLL family of histone H3K4 methyltransferases. Mol. Cell. 2007;27:107–119
  144. Tyagi S, Herr W. E2F1 mediates DNA damage and apoptosis through HCF-1 and the MLL family of histone methyltransferases. EMBO J. 2009;28:3185–3195
  145. Urist M, Tanaka T, Poyurovsky MV, Prives C. p73 induction after DNA damage is regulated by checkpoint kinases Chk1 and Chk2. Genes Dev. 2004;18:3041–3054
  146. Vassilev LT, Vu BT, Graves B, Carvajal D, Podlaski F, Filipovic Z, et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science. 2004;303:844–848
  147. Vaziri H, Dessain SK, Ng Eaton E, Imai SI, Frye RA, Pandita TK, et al. hSIR2(SIRT1) functions as an NAD-dependent p53 deacetylase. Cell. 2001;107:149–159
  148. Vilgelm A, El-Rifai W, Zaika A. Therapeutic prospects for p73 and p63: rising from the shadow of p53. Drug Resist. Updates. 2008;11:152–163
  149. Wang B, Liu K, Lin FT, Lin WC. A role for 14-3-3 tau in E2F1 stabilization and DNA damage-induced apoptosis. J. Biol. Chem. 2004;279:54140–54152
  150. Wang C, Chen L, Hou X, Li Z, Kabra N, Ma Y, et al. Interactions between E2F1 and SirT1 regulate apoptotic response to DNA damage. Nat. Cell Biol. 2006;8:1025–1031
  151. Wang C, Rauscher FJ, Cress WD, Chen J. Regulation of E2F1 function by the nuclear corepressor KAP1. J. Biol. Chem. 2007;282:29902–29909
  152. Wang J, Shen WH, Jin YJ, Brandt-Rauf PW, Yin Y. A molecular link between E2F-1 and the MAPK cascade. J. Biol. Chem. 2007;282:18521–18531
  153. Wang J, Yin DP, Liu YX, Baer R, Yin Y. Dual specificity phosphatase 1/CL100 is a direct transcriptional target of E2F-1 in the apoptotic response to oxidative stress. Cancer Res. 2007;67:6737–6744
  154. Wang XP, Liu GZ, Song AL, Chen RF, Li HY, Liu Y. Expression and significance of heat shock protein 70 and glucose-regulated protein 94 in human esophageal carcinoma. World J. Gastroenterol. 2005;11:429–432
  155. Wei Y, Liu D, Ge Y, Zhou F, Xu J, Chen H, et al. Identification of E1AF as a target gene of E2F1-induced apoptosis in response to DNA damage. J. Biochem. 2008;144:539–546
  156. Wikonkal NM, Remenyik E, Knezevic D, Zhang W, Liu M, Zhao H, et al. Inactivating E2f1 reverts apoptosis resistance and cancer sensitivity in Trp53-deficient mice. Nat. Cell Biol. 2003;5:655–660
  157. Wu J, Jin YJ, Calaf GM, Huang WL, Yin Y. PAC1 is a direct transcription target of E2F-1 in apoptotic signaling. Oncogene. 2007;26:6526–6535
  158. Wu ZL, Zheng SS, Li ZM, Qiao YY, Aau MY, Yu Q. Polycomb protein EZH2 regulates E2F1-dependent apoptosis through epigenetically modulating Bim expression. Cell Death Differ. 2010;17:801–810
  159. Xie W, Jiang P, Miao L, Zhao Y, Zhimin Z, Qing L, et al. Novel link between E2F1 and Smac/DIABLO: proapoptotic Smac/DIABLO is transcriptionally upregulated by E2F1. Nucleic Acids Res. 2006;34:2046–2055
  160. Xu X, Lee J, Stern DF. Microcephalin is a DNA damage response protein involved in regulation of CHK1 and BRCA1. J. Biol. Chem. 2004;279:34091–34094
  161. Yamasaki L, Jacks T, Bronson R, Goillot E, Harlow E, Dyson NJ. Tumor induction and tissue atrophy in mice lacking E2F-1. Cell. 1996;85:537–548
  162. Yamazaki K, Yajima T, Nagao T, Shinkawa H, Kondo F, Hanami K, et al. Expression of transcription factor E2F-1 in pancreatic ductal carcinoma: an immunohistochemical study. Pathol. Res. Pract. 2003;199:23–28
  163. Yang HL, Dong YB, Elliott MJ, Liu TJ, Atienza C, Stilwell A, et al. Adenovirus-mediated E2F-1 gene transfer inhibits MDM2 expression and efficiently induces apoptosis in MDM2-overexpressing tumor cells. Clin. Cancer Res. 1999;5:2242–2250
  164. Yang HL, Dong YB, Elliott MJ, Wong SL, McMasters KM. Additive effect of adenovirus-mediated E2F-1 gene transfer and topoisomerase II inhibitors on apoptosis in human osteosarcoma cells. Cancer Gene Ther. 2001;8:241–251
  165. Yang SZ, Lin FT, Lin WC. MCPH1/BRIT1 cooperates with E2F1 in the activation of checkpoint, DNA repair and apoptosis. EMBO Rep. 2008;9:907–915
  166. Yang X, Feng M, Jiang X, Wu Z, Li Z, Aau M, et al. miR-449a and miR-449b are direct transcriptional targets of E2F1 and negatively regulate pRb-E2F1 activity through a feedback loop by targeting CDK6 and CDC25A. Genes Dev. 2009;23:2388–2393
  167. You H, Pellegrini M, Tsuchihara K, Yamamoto K, Hacker G, Erlacher M, et al. FOXO3a-dependent regulation of Puma in response to cytokine/growth factor withdrawal. J. Exp. Med. 2006;203:1657–1663
  168. You H, Yamamoto K, Mak TW. Regulation of transactivation-independent proapoptotic activity of p53 by FOXO3a. Proc. Natl. Acad. Sci. U.S.A. 2006;103:9051–9056
  169. Zalmas LP, Zhao X, Graham AL, Fisher R, Reilly C, Coutts AS, et al. DNA-damage response control of E2F7 and E2F8. EMBO Rep. 2008;9:252–259
  170. Zhang L, Ming L, Yu J. BH3 mimetics to improve cancer therapy; mechanisms and examples. Drug Resist. Updates. 2007;10:207–217
  171. Zhou BB, Elledge SJ. The DNA damage response: putting checkpoints in perspective. Nature. 2000;408:433–439

PII: S1368-7646(10)00034-8

doi: 10.1016/j.drup.2010.06.001

Drug Resistance Updates
Volume 13, Issue 4 , Pages 119-131 , August 2010

Article Tools

* Image Usage & Resolution